Dyawanapelly Sathish, Junnuthula Vijayabhaskar Reddy, Singh AkhileshVikram
Department of Materials Engineering, Indian Institute of Science (IISc), Bangalore, Karnataka, India.
Curr Drug Metab. 2015;16(7):522-37. doi: 10.2174/1389200216666141219122614.
In recent years, multifaceted clinical benefits of polymeric therapeutics have been reported. Over the past decades, cancer has been one of the leading causes of mortality in the world. Many clinically approved chemotherapeutics encounter potential challenges against deadly cancer. Moreover, safety and efficacy of anticancer agents have been limited by undesirable pharmacokinetics and biodistribution. To address these limitations, various polymer drug conjugates are being studied and developed to improve the antitumor efficacy. Among other therapeutics, polymer therapeutics are well established platforms that circumvent anticancer therapeutics from enzymatic metabolism via direct conjugation to therapeutic molecules. Interestingly, polymer therapeutics meets an unmet need of small molecules. Further clinical study showed that polymer-drug conjugation can achieve desired pharmacokinetics and biodistribution properties of several anticancer drugs. The present retrospective review mainly enlightens the most recent preclinical and clinical studies include safety, stability, pharmacokinetic behavior and distribution of polymer therapeutics.
近年来，已有报道称聚合物疗法具有多方面的临床益处。在过去几十年中，癌症一直是全球主要的死亡原因之一。许多临床批准的化疗药物在对抗致命癌症方面面临潜在挑战。此外，抗癌药物的安全性和有效性受到不良药代动力学和生物分布的限制。为了解决这些局限性，正在研究和开发各种聚合物药物偶联物以提高抗肿瘤疗效。在其他疗法中，聚合物疗法是成熟的平台，可通过与治疗分子直接偶联来规避抗癌疗法的酶促代谢。有趣的是，聚合物疗法满足了小分子尚未满足的需求。进一步的临床研究表明，聚合物-药物偶联可以实现几种抗癌药物所需的药代动力学和生物分布特性。本回顾性综述主要介绍了聚合物疗法的最新临床前和临床研究，包括安全性、稳定性、药代动力学行为和分布。
